Joseph H Antin Selected Research

Tacrolimus (Prograf)

12/2022	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.
1/2021	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.
1/2020	Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
1/2020	A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation.
11/2019	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
3/2019	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
1/2019	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
1/2019	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
1/2019	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
1/2018	Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joseph H Antin Research Topics

Disease

95	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2022 - 10/2002
45	Bronchiolitis Obliterans Syndrome 11/2022 - 04/2004
32	Neoplasms (Cancer) 01/2022 - 08/2003
24	Leukemia 12/2022 - 01/2004
23	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 09/2003
21	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2022 - 09/2003
20	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2021 - 09/2003
13	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2015 - 03/2002
12	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 11/2022 - 02/2010
11	Infections 01/2022 - 07/2002
11	Lymphoma (Lymphomas) 01/2021 - 07/2007
10	Aplastic Anemia (Anemia, Hypoplastic) 10/2019 - 05/2007
5	Iron Overload 08/2014 - 05/2007
4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 10/2006
4	B-Cell Lymphoma (Lymphoma, B Cell) 12/2019 - 01/2016
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2019 - 03/2009
3	Bronchiolitis Obliterans 12/2022 - 02/2012
3	Viremia 01/2022 - 05/2010
3	Thrombotic Microangiopathies 01/2020 - 07/2005
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2017 - 04/2008
3	Mycoses (Diseases, Fungus) 09/2012 - 05/2006
3	Multiple Myeloma 12/2011 - 12/2004
3	Pneumonia (Pneumonitis) 10/2008 - 12/2002
2	Injection Site Reaction 12/2022 - 11/2017
2	Hematuria 11/2022 - 12/2020
2	Hypotension (Low Blood Pressure) 11/2022 - 03/2016
2	Cytokine Release Syndrome 01/2022 - 01/2021
2	Cytopenia 01/2021 - 12/2020
2	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 01/2019
2	Virus Diseases (Viral Diseases) 01/2020 - 06/2013
2	Inflammation (Inflammations) 01/2018 - 10/2008
2	Fibrosis (Cirrhosis) 01/2017 - 02/2012
2	Exanthema (Rash) 02/2014 - 03/2011
2	Colitis 08/2013 - 09/2011
2	Disease Progression 12/2011 - 02/2010
2	Acute Lung Injury 10/2008 - 12/2002
2	Mucositis 05/2005 - 05/2004

Drug/Important Bio-Agent (IBA)

26	Tacrolimus (Prograf)FDA LinkGeneric 12/2022 - 09/2003
25	Sirolimus (Rapamycin)FDA Link 01/2020 - 09/2003
19	Methotrexate (Mexate)FDA LinkGeneric 12/2022 - 09/2003
15	SteroidsIBA 11/2022 - 08/2004
11	Interleukin-2 (IL2)IBA 11/2022 - 12/2011
11	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 09/2003
9	fludarabineIBA 01/2020 - 04/2008
9	Calcineurin InhibitorsIBA 01/2019 - 05/2004
8	VaccinesIBA 12/2022 - 02/2003
8	Busulfan (Busulfex)FDA Link 01/2020 - 12/2002
8	AntigensIBA 01/2018 - 04/2004
7	defibrotideIBA 10/2018 - 07/2010
6	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2021 - 09/2004
6	Bortezomib (Velcade)FDA Link 03/2019 - 10/2009
5	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2021 - 05/2009
5	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2021 - 05/2009
5	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2020 - 06/2013
5	HLA Antigens (Human Leukocyte Antigens)IBA 01/2020 - 07/2006
5	Proteins (Proteins, Gene)FDA Link 07/2016 - 10/2008
5	Minor Histocompatibility AntigensIBA 03/2010 - 01/2003
4	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2022 - 09/2009
4	CytokinesIBA 01/2022 - 11/2002
4	IronIBA 11/2021 - 06/2011
4	trans-crotonin (CTN)IBA 11/2019 - 12/2011
4	Biological ProductsIBA 11/2017 - 09/2009
4	DNA (Deoxyribonucleic Acid)IBA 12/2016 - 05/2010
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 06/2012
3	Pharmaceutical PreparationsIBA 03/2019 - 05/2006
3	Sorafenib (BAY 43-9006)FDA Link 04/2018 - 12/2014
3	AntibodiesIBA 12/2017 - 04/2005
3	HLA-A Antigens (HLA-A)IBA 09/2015 - 04/2009
3	Ferritins (Ferritin)IBA 08/2014 - 06/2011
3	B-Cell Activating FactorIBA 05/2014 - 10/2007
3	Rituximab (Mabthera)FDA Link 06/2013 - 07/2006
2	Alemtuzumab (Campath)FDA Link 04/2022 - 05/2013
2	IpilimumabIBA 10/2021 - 07/2016
2	Natalizumab (Tysabri)FDA Link 05/2021 - 01/2021
2	InterferonsIBA 12/2020 - 01/2016
2	ibrutinibIBA 01/2020 - 11/2014
2	Phosphotransferases (Kinase)IBA 01/2020 - 12/2008
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 01/2019
2	Interleukin-15 (Interleukin 15)IBA 04/2018 - 01/2018
2	Monoclonal AntibodiesIBA 01/2017 - 09/2003
2	Immune Checkpoint InhibitorsIBA 01/2017 - 07/2016
2	Immunoglobulins (Immunoglobulin)IBA 06/2014 - 02/2012
2	TOR Serine-Threonine KinasesIBA 12/2008 - 09/2004
2	Imatinib Mesylate (Gleevec)FDA Link 10/2008 - 08/2004
2	Polysaccharides (Glycans)IBA 03/2005 - 02/2003
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 12/2022
1	ChromatinIBA 12/2022

Therapy/Procedure

86	Hematopoietic Stem Cell Transplantation 11/2022 - 07/2002
54	Transplantation 01/2022 - 03/2002
52	Therapeutics 11/2022 - 01/2002
43	Stem Cell Transplantation 12/2020 - 04/2002
32	Cell Transplantation 10/2022 - 02/2003
15	Homologous Transplantation 04/2022 - 11/2003
10	Drug Therapy (Chemotherapy) 01/2021 - 10/2006
10	Bone Marrow Transplantation (Transplantation, Bone Marrow) 10/2019 - 03/2002
6	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 04/2016 - 05/2004
3	Immunotherapy 01/2022 - 01/2006
3	Aftercare (After-Treatment) 01/2014 - 01/2010
2	Platelet Transfusion (Blood Platelet Transfusions) 01/2020 - 01/2019
2	Chemoradiotherapy 01/2018 - 05/2005